Genera Biosystems hits ASX to boost Dx tech
This article was originally published in Clinica
Molecular diagnostics specialist Genera Biosystems has floated on the Australian Securities Exchange (ASX) with shares opening on the market at Aus$0.40 ($0.37) per share. The Bundoora, Victoria-based company is currently developing its PapType test, which is designed to help pathology laboratories to identify human papillomavirus (HPV) in cervical smear samples. Genera is also working on a test for sexually transmitted diseases which is in the pre-clinical development stage. The firm’s chairman Fernando Careri said that the proceeds from the flotation on the ASX will help it progress towards full commercialisation of its tests over the next two years. Shares were marginally up at Aus$0.45 on the first day of trading (June 11).
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals